English
简体中文
Total: £ 56.28
Published Date: 2026-03-27 | Pages: 151 | Tables: 151 | Service & Software
The global Sterile Injectable CDMO market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
A Contract Development and Manufacturing Organization (CDMO) that specializes in sterile injectables focuses on the development and manufacturing of injectable drugs in a sterile environment. These organizations typically offer services ranging from formulation development to final sterile fill and finish. They adhere to strict regulatory standards to ensure the safety, efficacy, and quality of the injectable products they produce. Sterile injectables are crucial for various medical applications, including intravenous, intramuscular, and subcutaneous administration of medications. A CDMO specializing in this area plays a vital role in bringing these essential pharmaceutical products to market.
The North American market for Sterile Injectable CDMO is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Sterile Injectable CDMO is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Sterile Injectable CDMO in Pharmaceutical Company is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Sterile Injectable CDMO include Abbvie, Famar, Polfa Tarchomin, Pfizer, Quotient Sciences, Temad Co., Tianjin Hankang Pharmaceutical Biotechnology, Fareva, Sharp, Astral SteriTech, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Sterile Injectable CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Sterile Injectable CDMO. The Sterile Injectable CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Sterile Injectable CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Sterile Injectable CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Abbvie
Famar
Polfa Tarchomin
Pfizer
Quotient Sciences
Temad Co.
Tianjin Hankang Pharmaceutical Biotechnology
Fareva
Sharp
Astral SteriTech
Evonik
Aurigene Pharmaceutical Services
Prague Scientific
Ethypharm
TriRx Pharmaceutical Services
Biophrama Group
Gensenta Pharmaceuticals
BioTechnique
Mithra CDMo
S.C. Rompharm Company SRL
Flagship Biotech International Pvt. Ltd
Curida AS
BirgiMefar Group
Brooks Laboratories Limited
Segment by Type
Preclinical Manufacturing
Clinical Manufacturing
Commercial Manufacturing
Segment by Application
Pharmaceutical Company
Research Institute
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Sterile Injectable CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sterile Injectable CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Preclinical Manufacturing
1.2.3 Clinical Manufacturing
1.2.4 Commercial Manufacturing
1.3 Market by Application
1.3.1 Global Sterile Injectable CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical Company
1.3.3 Research Institute
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sterile Injectable CDMO Market Perspective (2021–2032)
2.2 Global Sterile Injectable CDMO Growth Trends by Region
2.2.1 Global Sterile Injectable CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Sterile Injectable CDMO Historic Market Size by Region (2021–2026)
2.2.3 Sterile Injectable CDMO Forecasted Market Size by Region (2027–2032)
2.3 Sterile Injectable CDMO Market Dynamics
2.3.1 Sterile Injectable CDMO Industry Trends
2.3.2 Sterile Injectable CDMO Market Drivers
2.3.3 Sterile Injectable CDMO Market Challenges
2.3.4 Sterile Injectable CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sterile Injectable CDMO Players by Revenue
3.1.1 Global Top Sterile Injectable CDMO Players by Revenue (2021–2026)
3.1.2 Global Sterile Injectable CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Sterile Injectable CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Sterile Injectable CDMO Revenue
3.4 Global Sterile Injectable CDMO Market Concentration Ratio
3.4.1 Global Sterile Injectable CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sterile Injectable CDMO Revenue in 2025
3.5 Global Key Players of Sterile Injectable CDMO Head Offices and Areas Served
3.6 Global Key Players of Sterile Injectable CDMO, Products and Applications
3.7 Global Key Players of Sterile Injectable CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Sterile Injectable CDMO Breakdown Data by Type
4.1 Global Sterile Injectable CDMO Historic Market Size by Type (2021–2026)
4.2 Global Sterile Injectable CDMO Forecasted Market Size by Type (2027–2032)
5 Sterile Injectable CDMO Breakdown Data by Application
5.1 Global Sterile Injectable CDMO Historic Market Size by Application (2021–2026)
5.2 Global Sterile Injectable CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Sterile Injectable CDMO Market Size (2021–2032)
6.2 North America Sterile Injectable CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Sterile Injectable CDMO Market Size by Country (2021–2026)
6.4 North America Sterile Injectable CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sterile Injectable CDMO Market Size (2021–2032)
7.2 Europe Sterile Injectable CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Sterile Injectable CDMO Market Size by Country (2021–2026)
7.4 Europe Sterile Injectable CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Sterile Injectable CDMO Market Size (2021–2032)
8.2 Asia-Pacific Sterile Injectable CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Sterile Injectable CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Sterile Injectable CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Sterile Injectable CDMO Market Size (2021–2032)
9.2 Latin America Sterile Injectable CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Sterile Injectable CDMO Market Size by Country (2021–2026)
9.4 Latin America Sterile Injectable CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sterile Injectable CDMO Market Size (2021–2032)
10.2 Middle East & Africa Sterile Injectable CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Sterile Injectable CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Details
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Sterile Injectable CDMO Introduction
11.1.4 Abbvie Revenue in Sterile Injectable CDMO Business (2021–2026)
11.1.5 Abbvie Recent Development
11.2 Famar
11.2.1 Famar Company Details
11.2.2 Famar Business Overview
11.2.3 Famar Sterile Injectable CDMO Introduction
11.2.4 Famar Revenue in Sterile Injectable CDMO Business (2021–2026)
11.2.5 Famar Recent Development
11.3 Polfa Tarchomin
11.3.1 Polfa Tarchomin Company Details
11.3.2 Polfa Tarchomin Business Overview
11.3.3 Polfa Tarchomin Sterile Injectable CDMO Introduction
11.3.4 Polfa Tarchomin Revenue in Sterile Injectable CDMO Business (2021–2026)
11.3.5 Polfa Tarchomin Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Sterile Injectable CDMO Introduction
11.4.4 Pfizer Revenue in Sterile Injectable CDMO Business (2021–2026)
11.4.5 Pfizer Recent Development
11.5 Quotient Sciences
11.5.1 Quotient Sciences Company Details
11.5.2 Quotient Sciences Business Overview
11.5.3 Quotient Sciences Sterile Injectable CDMO Introduction
11.5.4 Quotient Sciences Revenue in Sterile Injectable CDMO Business (2021–2026)
11.5.5 Quotient Sciences Recent Development
11.6 Temad Co.
11.6.1 Temad Co. Company Details
11.6.2 Temad Co. Business Overview
11.6.3 Temad Co. Sterile Injectable CDMO Introduction
11.6.4 Temad Co. Revenue in Sterile Injectable CDMO Business (2021–2026)
11.6.5 Temad Co. Recent Development
11.7 Tianjin Hankang Pharmaceutical Biotechnology
11.7.1 Tianjin Hankang Pharmaceutical Biotechnology Company Details
11.7.2 Tianjin Hankang Pharmaceutical Biotechnology Business Overview
11.7.3 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Introduction
11.7.4 Tianjin Hankang Pharmaceutical Biotechnology Revenue in Sterile Injectable CDMO Business (2021–2026)
11.7.5 Tianjin Hankang Pharmaceutical Biotechnology Recent Development
11.8 Fareva
11.8.1 Fareva Company Details
11.8.2 Fareva Business Overview
11.8.3 Fareva Sterile Injectable CDMO Introduction
11.8.4 Fareva Revenue in Sterile Injectable CDMO Business (2021–2026)
11.8.5 Fareva Recent Development
11.9 Sharp
11.9.1 Sharp Company Details
11.9.2 Sharp Business Overview
11.9.3 Sharp Sterile Injectable CDMO Introduction
11.9.4 Sharp Revenue in Sterile Injectable CDMO Business (2021–2026)
11.9.5 Sharp Recent Development
11.10 Astral SteriTech
11.10.1 Astral SteriTech Company Details
11.10.2 Astral SteriTech Business Overview
11.10.3 Astral SteriTech Sterile Injectable CDMO Introduction
11.10.4 Astral SteriTech Revenue in Sterile Injectable CDMO Business (2021–2026)
11.10.5 Astral SteriTech Recent Development
11.11 Evonik
11.11.1 Evonik Company Details
11.11.2 Evonik Business Overview
11.11.3 Evonik Sterile Injectable CDMO Introduction
11.11.4 Evonik Revenue in Sterile Injectable CDMO Business (2021–2026)
11.11.5 Evonik Recent Development
11.12 Aurigene Pharmaceutical Services
11.12.1 Aurigene Pharmaceutical Services Company Details
11.12.2 Aurigene Pharmaceutical Services Business Overview
11.12.3 Aurigene Pharmaceutical Services Sterile Injectable CDMO Introduction
11.12.4 Aurigene Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021–2026)
11.12.5 Aurigene Pharmaceutical Services Recent Development
11.13 Prague Scientific
11.13.1 Prague Scientific Company Details
11.13.2 Prague Scientific Business Overview
11.13.3 Prague Scientific Sterile Injectable CDMO Introduction
11.13.4 Prague Scientific Revenue in Sterile Injectable CDMO Business (2021–2026)
11.13.5 Prague Scientific Recent Development
11.14 Ethypharm
11.14.1 Ethypharm Company Details
11.14.2 Ethypharm Business Overview
11.14.3 Ethypharm Sterile Injectable CDMO Introduction
11.14.4 Ethypharm Revenue in Sterile Injectable CDMO Business (2021–2026)
11.14.5 Ethypharm Recent Development
11.15 TriRx Pharmaceutical Services
11.15.1 TriRx Pharmaceutical Services Company Details
11.15.2 TriRx Pharmaceutical Services Business Overview
11.15.3 TriRx Pharmaceutical Services Sterile Injectable CDMO Introduction
11.15.4 TriRx Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (2021–2026)
11.15.5 TriRx Pharmaceutical Services Recent Development
11.16 Biophrama Group
11.16.1 Biophrama Group Company Details
11.16.2 Biophrama Group Business Overview
11.16.3 Biophrama Group Sterile Injectable CDMO Introduction
11.16.4 Biophrama Group Revenue in Sterile Injectable CDMO Business (2021–2026)
11.16.5 Biophrama Group Recent Development
11.17 Gensenta Pharmaceuticals
11.17.1 Gensenta Pharmaceuticals Company Details
11.17.2 Gensenta Pharmaceuticals Business Overview
11.17.3 Gensenta Pharmaceuticals Sterile Injectable CDMO Introduction
11.17.4 Gensenta Pharmaceuticals Revenue in Sterile Injectable CDMO Business (2021–2026)
11.17.5 Gensenta Pharmaceuticals Recent Development
11.18 BioTechnique
11.18.1 BioTechnique Company Details
11.18.2 BioTechnique Business Overview
11.18.3 BioTechnique Sterile Injectable CDMO Introduction
11.18.4 BioTechnique Revenue in Sterile Injectable CDMO Business (2021–2026)
11.18.5 BioTechnique Recent Development
11.19 Mithra CDMo
11.19.1 Mithra CDMo Company Details
11.19.2 Mithra CDMo Business Overview
11.19.3 Mithra CDMo Sterile Injectable CDMO Introduction
11.19.4 Mithra CDMo Revenue in Sterile Injectable CDMO Business (2021–2026)
11.19.5 Mithra CDMo Recent Development
11.20 S.C. Rompharm Company SRL
11.20.1 S.C. Rompharm Company SRL Company Details
11.20.2 S.C. Rompharm Company SRL Business Overview
11.20.3 S.C. Rompharm Company SRL Sterile Injectable CDMO Introduction
11.20.4 S.C. Rompharm Company SRL Revenue in Sterile Injectable CDMO Business (2021–2026)
11.20.5 S.C. Rompharm Company SRL Recent Development
11.21 Flagship Biotech International Pvt. Ltd
11.21.1 Flagship Biotech International Pvt. Ltd Company Details
11.21.2 Flagship Biotech International Pvt. Ltd Business Overview
11.21.3 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Introduction
11.21.4 Flagship Biotech International Pvt. Ltd Revenue in Sterile Injectable CDMO Business (2021–2026)
11.21.5 Flagship Biotech International Pvt. Ltd Recent Development
11.22 Curida AS
11.22.1 Curida AS Company Details
11.22.2 Curida AS Business Overview
11.22.3 Curida AS Sterile Injectable CDMO Introduction
11.22.4 Curida AS Revenue in Sterile Injectable CDMO Business (2021–2026)
11.22.5 Curida AS Recent Development
11.23 BirgiMefar Group
11.23.1 BirgiMefar Group Company Details
11.23.2 BirgiMefar Group Business Overview
11.23.3 BirgiMefar Group Sterile Injectable CDMO Introduction
11.23.4 BirgiMefar Group Revenue in Sterile Injectable CDMO Business (2021–2026)
11.23.5 BirgiMefar Group Recent Development
11.24 Brooks Laboratories Limited
11.24.1 Brooks Laboratories Limited Company Details
11.24.2 Brooks Laboratories Limited Business Overview
11.24.3 Brooks Laboratories Limited Sterile Injectable CDMO Introduction
11.24.4 Brooks Laboratories Limited Revenue in Sterile Injectable CDMO Business (2021–2026)
11.24.5 Brooks Laboratories Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Sterile Injectable CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Preclinical Manufacturing
Table 3. Key Players of Clinical Manufacturing
Table 4. Key Players of Commercial Manufacturing
Table 5. Global Sterile Injectable CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Sterile Injectable CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Sterile Injectable CDMO Market Size by Region (US$ Million), 2021–2026
Table 8. Global Sterile Injectable CDMO Market Share by Region (2021–2026)
Table 9. Global Sterile Injectable CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Sterile Injectable CDMO Market Share by Region (2027–2032)
Table 11. Sterile Injectable CDMO Market Trends
Table 12. Sterile Injectable CDMO Market Drivers
Table 13. Sterile Injectable CDMO Market Challenges
Table 14. Sterile Injectable CDMO Market Restraints
Table 15. Global Sterile Injectable CDMO Revenue by Players (US$ Million), 2021–2026
Table 16. Global Sterile Injectable CDMO Market Share by Players (2021–2026)
Table 17. Global Top Sterile Injectable CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Sterile Injectable CDMO Revenue, 2025
Table 18. Ranking of Global Top Sterile Injectable CDMO Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Sterile Injectable CDMO Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Sterile Injectable CDMO, Headquarters and Area Served
Table 21. Global Key Players of Sterile Injectable CDMO, Products and Applications
Table 22. Global Key Players of Sterile Injectable CDMO, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Sterile Injectable CDMO Market Size by Type (US$ Million), 2021–2026
Table 25. Global Sterile Injectable CDMO Revenue Market Share by Type (2021–2026)
Table 26. Global Sterile Injectable CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Sterile Injectable CDMO Revenue Market Share by Type (2027–2032)
Table 28. Global Sterile Injectable CDMO Market Size by Application (US$ Million), 2021–2026
Table 29. Global Sterile Injectable CDMO Revenue Market Share by Application (2021–2026)
Table 30. Global Sterile Injectable CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Sterile Injectable CDMO Revenue Market Share by Application (2027–2032)
Table 32. North America Sterile Injectable CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Sterile Injectable CDMO Market Size by Country (US$ Million), 2021–2026
Table 34. North America Sterile Injectable CDMO Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Sterile Injectable CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Sterile Injectable CDMO Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Sterile Injectable CDMO Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Sterile Injectable CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Sterile Injectable CDMO Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Sterile Injectable CDMO Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Sterile Injectable CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Sterile Injectable CDMO Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Sterile Injectable CDMO Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Sterile Injectable CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Sterile Injectable CDMO Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Sterile Injectable CDMO Market Size by Country (US$ Million), 2027–2032
Table 47. Abbvie Company Details
Table 48. Abbvie Business Overview
Table 49. Abbvie Sterile Injectable CDMO Product
Table 50. Abbvie Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 51. Abbvie Recent Development
Table 52. Famar Company Details
Table 53. Famar Business Overview
Table 54. Famar Sterile Injectable CDMO Product
Table 55. Famar Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 56. Famar Recent Development
Table 57. Polfa Tarchomin Company Details
Table 58. Polfa Tarchomin Business Overview
Table 59. Polfa Tarchomin Sterile Injectable CDMO Product
Table 60. Polfa Tarchomin Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 61. Polfa Tarchomin Recent Development
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Sterile Injectable CDMO Product
Table 65. Pfizer Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 66. Pfizer Recent Development
Table 67. Quotient Sciences Company Details
Table 68. Quotient Sciences Business Overview
Table 69. Quotient Sciences Sterile Injectable CDMO Product
Table 70. Quotient Sciences Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 71. Quotient Sciences Recent Development
Table 72. Temad Co. Company Details
Table 73. Temad Co. Business Overview
Table 74. Temad Co. Sterile Injectable CDMO Product
Table 75. Temad Co. Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 76. Temad Co. Recent Development
Table 77. Tianjin Hankang Pharmaceutical Biotechnology Company Details
Table 78. Tianjin Hankang Pharmaceutical Biotechnology Business Overview
Table 79. Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product
Table 80. Tianjin Hankang Pharmaceutical Biotechnology Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 81. Tianjin Hankang Pharmaceutical Biotechnology Recent Development
Table 82. Fareva Company Details
Table 83. Fareva Business Overview
Table 84. Fareva Sterile Injectable CDMO Product
Table 85. Fareva Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 86. Fareva Recent Development
Table 87. Sharp Company Details
Table 88. Sharp Business Overview
Table 89. Sharp Sterile Injectable CDMO Product
Table 90. Sharp Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 91. Sharp Recent Development
Table 92. Astral SteriTech Company Details
Table 93. Astral SteriTech Business Overview
Table 94. Astral SteriTech Sterile Injectable CDMO Product
Table 95. Astral SteriTech Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 96. Astral SteriTech Recent Development
Table 97. Evonik Company Details
Table 98. Evonik Business Overview
Table 99. Evonik Sterile Injectable CDMO Product
Table 100. Evonik Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 101. Evonik Recent Development
Table 102. Aurigene Pharmaceutical Services Company Details
Table 103. Aurigene Pharmaceutical Services Business Overview
Table 104. Aurigene Pharmaceutical Services Sterile Injectable CDMO Product
Table 105. Aurigene Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 106. Aurigene Pharmaceutical Services Recent Development
Table 107. Prague Scientific Company Details
Table 108. Prague Scientific Business Overview
Table 109. Prague Scientific Sterile Injectable CDMO Product
Table 110. Prague Scientific Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 111. Prague Scientific Recent Development
Table 112. Ethypharm Company Details
Table 113. Ethypharm Business Overview
Table 114. Ethypharm Sterile Injectable CDMO Product
Table 115. Ethypharm Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 116. Ethypharm Recent Development
Table 117. TriRx Pharmaceutical Services Company Details
Table 118. TriRx Pharmaceutical Services Business Overview
Table 119. TriRx Pharmaceutical Services Sterile Injectable CDMO Product
Table 120. TriRx Pharmaceutical Services Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 121. TriRx Pharmaceutical Services Recent Development
Table 122. Biophrama Group Company Details
Table 123. Biophrama Group Business Overview
Table 124. Biophrama Group Sterile Injectable CDMO Product
Table 125. Biophrama Group Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 126. Biophrama Group Recent Development
Table 127. Gensenta Pharmaceuticals Company Details
Table 128. Gensenta Pharmaceuticals Business Overview
Table 129. Gensenta Pharmaceuticals Sterile Injectable CDMO Product
Table 130. Gensenta Pharmaceuticals Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 131. Gensenta Pharmaceuticals Recent Development
Table 132. BioTechnique Company Details
Table 133. BioTechnique Business Overview
Table 134. BioTechnique Sterile Injectable CDMO Product
Table 135. BioTechnique Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 136. BioTechnique Recent Development
Table 137. Mithra CDMo Company Details
Table 138. Mithra CDMo Business Overview
Table 139. Mithra CDMo Sterile Injectable CDMO Product
Table 140. Mithra CDMo Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 141. Mithra CDMo Recent Development
Table 142. S.C. Rompharm Company SRL Company Details
Table 143. S.C. Rompharm Company SRL Business Overview
Table 144. S.C. Rompharm Company SRL Sterile Injectable CDMO Product
Table 145. S.C. Rompharm Company SRL Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 146. S.C. Rompharm Company SRL Recent Development
Table 147. Flagship Biotech International Pvt. Ltd Company Details
Table 148. Flagship Biotech International Pvt. Ltd Business Overview
Table 149. Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product
Table 150. Flagship Biotech International Pvt. Ltd Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 151. Flagship Biotech International Pvt. Ltd Recent Development
Table 152. Curida AS Company Details
Table 153. Curida AS Business Overview
Table 154. Curida AS Sterile Injectable CDMO Product
Table 155. Curida AS Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 156. Curida AS Recent Development
Table 157. BirgiMefar Group Company Details
Table 158. BirgiMefar Group Business Overview
Table 159. BirgiMefar Group Sterile Injectable CDMO Product
Table 160. BirgiMefar Group Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 161. BirgiMefar Group Recent Development
Table 162. Brooks Laboratories Limited Company Details
Table 163. Brooks Laboratories Limited Business Overview
Table 164. Brooks Laboratories Limited Sterile Injectable CDMO Product
Table 165. Brooks Laboratories Limited Revenue in Sterile Injectable CDMO Business (US$ Million), 2021–2026
Table 166. Brooks Laboratories Limited Recent Development
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
Table 170. Authors List of This Report
List of Figures
Figure 1. Sterile Injectable CDMO Picture
Figure 2. Global Sterile Injectable CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Sterile Injectable CDMO Market Share by Type: 2025 vs 2032
Figure 4. Preclinical Manufacturing Features
Figure 5. Clinical Manufacturing Features
Figure 6. Commercial Manufacturing Features
Figure 7. Global Sterile Injectable CDMO Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Sterile Injectable CDMO Market Share by Application: 2025 vs 2032
Figure 9. Pharmaceutical Company Case Studies
Figure 10. Research Institute Case Studies
Figure 11. Other Case Studies
Figure 12. Sterile Injectable CDMO Report Years Considered
Figure 13. Global Sterile Injectable CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Sterile Injectable CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Sterile Injectable CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global Sterile Injectable CDMO Market Share by Players in 2025
Figure 17. Global Sterile Injectable CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Sterile Injectable CDMO Revenue in 2025
Figure 19. North America Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Sterile Injectable CDMO Market Share by Country (2021–2032)
Figure 21. United States Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Sterile Injectable CDMO Market Share by Country (2021–2032)
Figure 25. Germany Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Sterile Injectable CDMO Market Share by Region (2021–2032)
Figure 33. China Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Sterile Injectable CDMO Market Share by Country (2021–2032)
Figure 41. Mexico Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Sterile Injectable CDMO Market Share by Country (2021–2032)
Figure 45. Israel Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Sterile Injectable CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Abbvie Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 49. Famar Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 50. Polfa Tarchomin Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 51. Pfizer Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 52. Quotient Sciences Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 53. Temad Co. Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 54. Tianjin Hankang Pharmaceutical Biotechnology Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 55. Fareva Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 56. Sharp Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 57. Astral SteriTech Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 58. Evonik Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 59. Aurigene Pharmaceutical Services Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 60. Prague Scientific Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 61. Ethypharm Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 62. TriRx Pharmaceutical Services Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 63. Biophrama Group Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 64. Gensenta Pharmaceuticals Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 65. BioTechnique Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 66. Mithra CDMo Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 67. S.C. Rompharm Company SRL Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 68. Flagship Biotech International Pvt. Ltd Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 69. Curida AS Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 70. BirgiMefar Group Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 71. Brooks Laboratories Limited Revenue Growth Rate in Sterile Injectable CDMO Business (2021–2026)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
